Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Myanmar has been steadily increasing in recent years.
Customer preferences: Myanmar has a high prevalence of rheumatoid arthritis, which has led to an increase in demand for Anti-Rheumatic Drugs. Additionally, the aging population in the country has also contributed to the growth of the market.
Trends in the market: The Anti-Rheumatic Drugs market in Myanmar is primarily driven by the demand for non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). There has been a shift towards the use of biologic DMARDs, which are more expensive but have fewer side effects compared to traditional DMARDs. The market is also seeing an increase in the availability of biosimilars, which are more affordable versions of biologic DMARDs.
Local special circumstances: Myanmar is a low-income country with a limited healthcare budget. This has resulted in a lack of access to healthcare for many people in the country, including those with rheumatoid arthritis. Additionally, there is a shortage of healthcare professionals in Myanmar, which makes it difficult for patients to receive proper diagnosis and treatment.
Underlying macroeconomic factors: Myanmar's economy has been growing steadily in recent years, with an average annual growth rate of 6.8% between 2017 and 2019. However, the country remains one of the poorest in Southeast Asia, with a large portion of the population living in poverty. The healthcare system in Myanmar is underfunded and understaffed, which has led to a lack of access to healthcare for many people in the country. The government has recognized the importance of improving healthcare in the country and has increased healthcare spending in recent years. However, there is still a long way to go in terms of improving healthcare infrastructure and access to healthcare in Myanmar.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
